Our roundup of Canadian small-caps of between $100-million and $3-billion in market capitalization making news
DRI Healthcare Trust (DHT-UN-T) announced it has acquired a royalty interest in worldwide sales of Xenpozyme (olipudase alfa) for US$30-million. The company said additional performance-based milestones of up to US$26.5-million could be paid if sales of the drug outperform expectations.
The company said Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease.
“Xenpozyme is a product that provides ASMD patients and their families with a disease-modifying therapy where none previously existed. The drug represents a transformational shift in therapies available to patients who suffer from ASMD,” said CEO Behzad Khosrowshahi.
**
Metalla Royalty & Streaming Ltd. (MTA-A) announced that it signed a royalty purchase agreement with First Majestic Silver Corp. (FR-T). Metalla said it will acquire eight royalties for $20-million of common shares of Metalla First Majestic holds and will originate a portfolio of royalties in Mexico.
**
Mene Inc. (MENE-X) reported revenue came in at $5-million for the third quarter, compared to $5.3-million a year ago. Net income of $1-illion compared to $551,723 a year ago.
**
NGEx Minerals Ltd. (NGEX-X) reported a net loss of $6.1-million or 4 cents per share during the three months ended Sept. 30 versus a net loss of $1.5-million or a penny per share a year ago.